NCT05712746Active, not recruiting
Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure.
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
To confirm the safety of tolvaptan sodium phosphate in patients with volume overload in heart failure.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1600 (estimated)
- First submitted
- 16 Jan 2023
- Start date
- 3 Mar 2023
- Primary completion date
- 7 May 2026
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Diseases
- Heart failure
- NCT number
- NCT05712746
What you commit to
- Study type: Observational
- Planned participants: 1600
- From 3 Mar 2023 to the primary completion date, 7 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- patients with a known hypersensitivity to Tolvaptan sodium phosphate or Tolvaptan
Who the study is looking for
- \-
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmacovigilance Department Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.